Study suggests way to fight therapy resistant leukemia by blocking DNA repair

August 8, 2013

New research posted online by the Nature journal Leukemia suggests blocking part of a DNA repair complex that helps some types of leukemia resist treatment can increase the effectiveness of chemotherapy and enhance survival.

Scientists from Cincinnati Children's Hospital Medical Center report that their experimental combination treatment strategy – using a small molecular inhibitor along with – was particularly effective at stopping a stubborn leukemia called T-cell , or T-ALL. The study involved laboratory cell lines of human leukemia and mouse models of the disease.

Initial remission rates for T-ALL with current treatments are about 90 percent, but the overall survival rate is between 60 and 70 percent.

"Although initial remission rates are high with available treatments, the disease comes back because of that leads to relapse. There is an urgent need to develop new therapeutic strategies to combat refractory T-ALL and our study uncovers a way to enhance the effectiveness of chemotherapy," said Fukun Guo, PhD, study first author and a researcher in the Division of Experimental Hematology and Cancer Biology at Cincinnati Children's.

A key breakthrough in the research came when the scientists discovered something that was previously unknown – a molecular mechanism in the Fanconi anemia DNA repair pathway apparently makes T-ALL resistant to chemotherapy. This same pathway has been linked to drug resistance in other , Guo said.

Chemotherapy drugs are often designed to kill off by damaging their DNA until they transition to a programmed death mode called apoptosis. Some cancers are able to leverage molecular workarounds – such as DNA repair – to become treatment resistant. This has helped prompt the development of targeted to attack other components of – either as stand-alone therapies or to augment chemotherapy.

Fanconi anemia (FA) is a genomic instability syndrome caused by mutations inside a cluster of proteins normally responsible for DNA repair in cells. Mutation or silencing of FA genes is also associated with increased sensitivity to DNA damaging drugs. Guo and his fellow researchers worked under the premise that inhibiting the FA pathway and combining this with DNA damaging might be a promising strategy for cancer therapy.

To block the FA repair pathway in leukemic cells, researchers tested the inhibition of a protein called mTOR (mammalian target of rapamycin). The protein plays a critical role in the growth and survival of mammalian cells – although disruptions in the mTOR molecular pathway are linked to tumor growth, chemotherapy resistance and poor prognoses in malignancies such as leukemia.

Initial testing of mTOR inhibition was achieved by direct deletion of the mTOR gene in mice. The scientists noticed that this caused significant down regulation, or silencing, of a protein called FANCD2 – a component of the FA repair pathway.

The scientists then tested three new mTOR inhibitors currently under development (pp242, AZD8055 and INK128) in combination with the chemotherapies AraC, Etoposide and Cisplatin to see how they affected laboratory lines of leukemia cells and mouse models of the disease. They compared the effectiveness of the combination treatments with just treating the leukemia by chemotherapy or inhibitors alone. Tests showed that combining mTOR inhibitors with chemotherapy was far more effective at treating leukemia than when the inhibitors or chemotherapy were used as stand-alone treatments.

In one example highlighted by the researchers, mouse models of T-ALL were treated either with a combination of mTOR inhibitor pp242 and the chemotherapy drug AraC, or they were treated with just AraC or pp242. Mice treated only with pp242 or AraC died from their leukemia within 80 days. Mice treated with pp242 and AraC showed significantly prolonged survival, with 75 percent surviving more than 100 days and 50 percent surviving about 175 days.

Although the researchers emphasized that laboratory results involving cell lines and mice do not necessarily translate to human treatment, they say their findings show that new mTOR inhibitors combined with chemotherapy could become a new treatment strategy for T-ALL. They also report that inhibition of the FA pathway coupled with chemotherapy maybe be useful for treating other types of cancer.

Guo and his collaborators continue their studies by establishing additional mouse models of leukemia that have been transplanted with patient cells of relapsed and refractory disease. They are testing combination treatment on the mice with mTOR inhibitors and a chemotherapy agent called AraG, which is currently in clinical use to treat T-ALL.

Explore further: Novel combination therapy shuts down escape route, killing glioblastoma tumor cells

Related Stories

Novel combination therapy shuts down escape route, killing glioblastoma tumor cells

February 26, 2013
Glioblastoma, the most common and lethal form of brain tumor in adults, is challenging to treat because the tumors rapidly become resistant to therapy. As cancer researchers are learning more about the causes of tumor cell ...

New drug combination therapy developed to treat leukemia

April 17, 2013
A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival ...

Renal cancer drug temsirolimus shows promise against mesothelioma

May 1, 2011
A drug commonly used to treat kidney cancer may increase the effectiveness of chemotherapy for mesothelioma, according to a study published in the May issue of the Journal of Thoracic Oncology.

Researcher pieces together AML prognosis puzzle

October 15, 2012
When patients suffering from Acute Myeloid Leukemia (AML) express high levels of the gene, MN1, an already aggressive leukemia is accelerated and shortens survival time. While that's a known fact, the mechanisms involved ...

Experimental drug inhibits cell signaling pathway and slows ovarian cancer growth

April 15, 2011
An experimental drug that blocks two points of a crucial cancer cell signaling pathway inhibits the growth of ovarian cancer cells and significantly increases survival in an ovarian cancer mouse model, a study at UCLA's Jonsson ...

Study suggests improved treatment alternative for lymphoid leukemia

February 11, 2013
Discovering what they call the "Achilles' heel" for lymphoid leukemia, an international research team has tested a possible alternative treatment that eradicated the disease in mouse models.

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.